Disease · MONDO_0004948

B-cell chronic lymphocytic leukemia

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. B-cell chronic lymphocytic leukemia. Diseases, record MONDO_0004948. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0004948

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: B-cell chronic lymphocytic leukemia; Open Targets
Open Targets ID: MONDO_0004948; Open Targets
Other names: B cell CLL, B cell chronic lymphocytic leukaemia, B cell lymphocytic leukaemia, B cell lymphocytic leukemia, B-CLL, B-cell chronic lymphogenous leukaemia, B-cell chronic lymphogenous leukemia, B-cell chronic lymphoid leukaemia, B-cell chronic lymphoid leukemia, BCLL, CLL, Chronic Lymphocytic Leukemia, chronic B-cell lymphocytic leukaemia, chronic B-cell lymphocytic leukemia, chronic lymphatic leukemia, chronic lymphocytic leukaemia (CLL), chronic lymphocytic leukemia (CLL), chronic lymphogenous leukaemia, chronic lymphogenous leukemia, hematopoeitic - chronic lymphocytic leukaemia (CLL), hematopoeitic - chronic lymphocytic leukemia (CLL), lymphoplasmacytic leukemia, small lymphocytic lymphoma; Open Targets
Disease Ontology: DOID:1040; Disease Ontology
MeSH: D015451; MeSH
NCI Thesaurus: C3163; NCI Thesaurus
Orphanet: ORPHA:67038; Orphanet
Highest stage of its drugs: Approval, for 14 of its 345 drugs, from ClinicalTrials.gov, DailyMed, EMA Human Drugs, FDA, PMDA and TTD; Open Targets

Drugs345

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
RITUXIMAB	CHEMBL1201576	Antibody	Approval	ClinicalTrials.gov, DailyMed and EMA Human Drugs	258	249	248	Drugs and targets
IBRUTINIB	CHEMBL1873475	Small molecule	Approval	ClinicalTrials.gov, DailyMed, EMA Human Drugs and PMDA	135	131	129	Drugs and targets
VENETOCLAX	CHEMBL3137309	Small molecule	Approval	DailyMed, EMA Human Drugs, FDA and PMDA	124	119	119	Drugs and targets
OBINUTUZUMAB	CHEMBL1743048	Antibody	Approval	DailyMed and EMA Human Drugs	103	101	101	Drugs and targets
ACALABRUTINIB	CHEMBL3707348	Small molecule	Approval	DailyMed, EMA Human Drugs and PMDA	68	62	61	Drugs and targets
OFATUMUMAB	CHEMBL1201836	Antibody	Approval	DailyMed, FDA and PMDA	62	58	58	Drugs and targets
ALEMTUZUMAB	CHEMBL1201587	Antibody	Approval	DailyMed and PMDA	58	55	55	Drugs and targets
FLUDARABINE PHOSPHATE	CHEMBL1096882	Small molecule	Approval	DailyMed and FDA	50	37	37	Drugs and targets
ZANUBRUTINIB	CHEMBL3936761	Small molecule	Approval	PMDA	40	37	35	Drugs and targets
IDELALISIB	CHEMBL2216870	Small molecule	Approval	ClinicalTrials.gov, DailyMed and EMA Human Drugs	37	35	35	Drugs and targets

1 to 10 of 345

See all 345 drugs

Targets417

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
MS4A1	B-lymphocyte antigen CD20	14	B-lymphocyte antigen CD20 binding agent; B-lymphocyte antigen CD20 cross-linking agent	Approval	https://conductscience.org/library/genes/931	Drugs and targets
PIK3CD	PI3-kinase class I	13	PI3-kinase class I inhibitor; PI3-kinase p110-delta subunit inhibitor	Approval	https://conductscience.org/library/genes/5293	Drugs and targets
BTK	Tyrosine-protein kinase BTK	12	Tyrosine-protein kinase BTK inhibitor	Approval	https://conductscience.org/library/genes/695	Drugs and targets
CD19	B-lymphocyte antigen CD19	8	B-lymphocyte antigen CD19 binding agent; B-lymphocyte antigen CD19 cross-linking agent	Phase 3	https://conductscience.org/library/genes/930	Drugs and targets
CD3D	T cell surface glycoprotein CD3	7	T cell surface glycoprotein CD3 binding agent; T cell surface glycoprotein CD3 cross-linking agent; T cell surface glycoprotein CD3 inhibitor	Phase 2	https://conductscience.org/library/genes/915	Drugs and targets
CD3E	T cell surface glycoprotein CD3	7	T cell surface glycoprotein CD3 binding agent; T cell surface glycoprotein CD3 cross-linking agent; T cell surface glycoprotein CD3 inhibitor	Phase 2	https://conductscience.org/library/genes/916	Drugs and targets
CD3G	T cell surface glycoprotein CD3	7	T cell surface glycoprotein CD3 binding agent; T cell surface glycoprotein CD3 cross-linking agent; T cell surface glycoprotein CD3 inhibitor	Phase 2	https://conductscience.org/library/genes/917	Drugs and targets
TUBA1A	Tubulin	7	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	7	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	7	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/84790	Drugs and targets

1 to 10 of 417

See all 417 targets

Trials1,022

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 26 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01905943	A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia	Phase 3	979	2018-10-29	Chronic Lymphocytic Leukemia	BENDAMUSTINE, CHLORAMBUCIL, CYCLOPHOSPHAMIDE, FLUDARABINE, OBINUTUZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00281918	Fludarabine and Cyclophosphamide With or Without Rituximab in Patients With Previously Untreated Chronic B-Cell Lymphocytic Leukemia	Phase 3	817	2011-03-29	Leukemia	CYCLOPHOSPHAMIDE, FLUDARABINE PHOSPHATE, RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT01010061	CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a)	Phase 3	787	2014-04-01	Lymphocytic Leukemia, Chronic	CHLORAMBUCIL, OBINUTUZUMAB, RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT01998880	CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b)	Phase 3	787	2014-01-28	Lymphocytic Leukemia, Chronic	CHLORAMBUCIL, OBINUTUZUMAB, RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT02053610	CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2)	Phase 3	787	2014-10-10	Lymphocytic Leukemia, Chronic	CHLORAMBUCIL, OBINUTUZUMAB, RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT01178086	A Study on Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL)		681	2018-10-05	Lymphocytic Leukemia, Chronic	RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT03734016	A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia	Phase 3	652	2023-07-27	Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma	IBRUTINIB, ZANUBRUTINIB	Its record names the disease	ClinicalTrials.gov
NCT02612311	Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia	Phase 3	603	2024-05-07	Chronic Lymphocytic Leukemia	UBLITUXIMAB, UMBRALISIB TOSYLATE	Its record names the disease	ClinicalTrials.gov
NCT03336333	A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL	Phase 3	590	2023-11-07	Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma	VENETOCLAX, ZANUBRUTINIB	Its record names the disease	ClinicalTrials.gov
NCT01611090	A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Phase 3	578	2020-03-03	Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma	BENDAMUSTINE HYDROCHLORIDE, IBRUTINIB, RITUXIMAB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 1,022

See all 1,022 trials

Comparisons in its trials184

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Fludarabine+Cyclophosphamide (FC) vs Fludarabine+Cyclophosphamide+Rituximab (FCR): serious adverse events	164 of 398	186 of 402	800	NCT00281918	Trial comparisons
Unselected Population (Participants With Any Comorbidity) vs Slow Go Subpopulation: serious adverse events	85 of 485	44 of 196	681	NCT01178086	Trial comparisons
Rituximab + Chlorambucil (RClb) vs Obinutuzumab + Chlorambucil (GClb): serious adverse events	124 of 321	150 of 336	657	NCT02053610	Trial comparisons
Zanubrutinib vs Ibrutinib: deaths from any cause	69 of 327	83 of 325	652	NCT03734016	Trial comparisons
Zanubrutinib vs Ibrutinib: serious adverse events	172 of 324	196 of 324	648	NCT03734016	Trial comparisons
Ibrutinib+BR vs Placebo+BR: Number of Participants With Clinically Relevant Shifts in Disease-Related Symptoms	0 of 289	0 of 289	578	NCT01611090	Trial comparisons
Ibrutinib+BR vs Placebo+BR: Number of Participants Who Received Subsequent Antineoplastic Therapy	52 of 287	61 of 287	574	NCT01611090	Trial comparisons
Fludarabine+Cyclophosphamide (FC) vs Fludarabine+Cyclophosphamide+Rituximab (FCR): serious adverse events	132 of 272	138 of 274	546	NCT00090051	Trial comparisons
Arm A (Ibrutinib, Rituximab) vs Arm B (Rituximab, Fludarabine Phosphate, Cyclophosphamide): deaths from any cause	4 of 354	10 of 175	529	NCT02048813	Trial comparisons
Acalabrutinib vs Ibrutinib: Number of Participants With Treatment-emergent Richter's Transformation	13 of 266	14 of 263	529	NCT02477696	Trial comparisons

1 to 10 of 184

See all 184 comparisons in its trials

Papers from its trials626

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
40209059	RESULT	1	PubMed
39602678	RESULT	1	PubMed
38821083	RESULT	1	PubMed
38620072	RESULT	1	PubMed
37163621	RESULT	1	PubMed
35988545	RESULT	1	PubMed
35594173	RESULT	1	PubMed
33512465	RESULT	1	PubMed
33054121	RESULT	1	PubMed
32856068	RESULT	1	PubMed

1 to 10 of 626

See all 626 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0004948

GET https://conductscience.org/api/diseases/v1/MONDO_0004948/drugs?page=2

API reference For AI assistants